|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AARS |
Gene summary for AARS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AARS | Gene ID | 16 |
| Gene name | alanyl-tRNA synthetase 1 | |
| Gene Alias | AARS | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P49588 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 16 | AARS | LZE4T | Human | Esophagus | ESCC | 1.03e-17 | 6.33e-01 | 0.0811 |
| 16 | AARS | LZE7T | Human | Esophagus | ESCC | 2.06e-08 | 5.65e-01 | 0.0667 |
| 16 | AARS | LZE8T | Human | Esophagus | ESCC | 1.58e-07 | 2.42e-01 | 0.067 |
| 16 | AARS | LZE20T | Human | Esophagus | ESCC | 5.94e-05 | 3.26e-01 | 0.0662 |
| 16 | AARS | LZE24D1 | Human | Esophagus | HGIN | 1.52e-02 | 6.23e-01 | 0.054 |
| 16 | AARS | LZE24T | Human | Esophagus | ESCC | 3.08e-22 | 6.92e-01 | 0.0596 |
| 16 | AARS | LZE21T | Human | Esophagus | ESCC | 2.53e-12 | 7.04e-01 | 0.0655 |
| 16 | AARS | P1T-E | Human | Esophagus | ESCC | 6.22e-10 | 5.30e-01 | 0.0875 |
| 16 | AARS | P2T-E | Human | Esophagus | ESCC | 3.99e-23 | 4.05e-01 | 0.1177 |
| 16 | AARS | P4T-E | Human | Esophagus | ESCC | 2.62e-31 | 7.22e-01 | 0.1323 |
| 16 | AARS | P5T-E | Human | Esophagus | ESCC | 3.57e-23 | 4.20e-01 | 0.1327 |
| 16 | AARS | P8T-E | Human | Esophagus | ESCC | 8.03e-18 | 3.37e-01 | 0.0889 |
| 16 | AARS | P9T-E | Human | Esophagus | ESCC | 8.46e-10 | 1.34e-01 | 0.1131 |
| 16 | AARS | P10T-E | Human | Esophagus | ESCC | 3.52e-23 | 4.87e-01 | 0.116 |
| 16 | AARS | P11T-E | Human | Esophagus | ESCC | 1.59e-16 | 7.53e-01 | 0.1426 |
| 16 | AARS | P12T-E | Human | Esophagus | ESCC | 5.89e-34 | 6.49e-01 | 0.1122 |
| 16 | AARS | P15T-E | Human | Esophagus | ESCC | 1.09e-23 | 5.58e-01 | 0.1149 |
| 16 | AARS | P16T-E | Human | Esophagus | ESCC | 2.53e-25 | 4.81e-01 | 0.1153 |
| 16 | AARS | P17T-E | Human | Esophagus | ESCC | 4.15e-11 | 4.93e-01 | 0.1278 |
| 16 | AARS | P19T-E | Human | Esophagus | ESCC | 2.17e-17 | 1.04e+00 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| GO:0070997 | Colorectum | AD | neuron death | 114/3918 | 361/18723 | 1.13e-06 | 3.72e-05 | 114 |
| GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
| GO:1901214 | Colorectum | AD | regulation of neuron death | 99/3918 | 319/18723 | 1.26e-05 | 2.76e-04 | 99 |
| GO:0051402 | Colorectum | AD | neuron apoptotic process | 77/3918 | 246/18723 | 8.07e-05 | 1.28e-03 | 77 |
| GO:1901215 | Colorectum | AD | negative regulation of neuron death | 67/3918 | 208/18723 | 8.81e-05 | 1.35e-03 | 67 |
| GO:0006418 | Colorectum | AD | tRNA aminoacylation for protein translation | 19/3918 | 41/18723 | 2.37e-04 | 3.03e-03 | 19 |
| GO:0043039 | Colorectum | AD | tRNA aminoacylation | 19/3918 | 44/18723 | 7.13e-04 | 7.21e-03 | 19 |
| GO:0043523 | Colorectum | AD | regulation of neuron apoptotic process | 64/3918 | 212/18723 | 8.95e-04 | 8.63e-03 | 64 |
| GO:0043038 | Colorectum | AD | amino acid activation | 19/3918 | 45/18723 | 9.94e-04 | 9.28e-03 | 19 |
| GO:0006520 | Colorectum | AD | cellular amino acid metabolic process | 81/3918 | 284/18723 | 1.37e-03 | 1.19e-02 | 81 |
| GO:0006414 | Colorectum | AD | translational elongation | 21/3918 | 55/18723 | 2.53e-03 | 1.93e-02 | 21 |
| GO:0043524 | Colorectum | AD | negative regulation of neuron apoptotic process | 43/3918 | 145/18723 | 8.04e-03 | 4.73e-02 | 43 |
| GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
| GO:00064181 | Colorectum | SER | tRNA aminoacylation for protein translation | 17/2897 | 41/18723 | 5.75e-05 | 1.35e-03 | 17 |
| GO:00709971 | Colorectum | SER | neuron death | 84/2897 | 361/18723 | 5.76e-05 | 1.35e-03 | 84 |
| GO:00430391 | Colorectum | SER | tRNA aminoacylation | 17/2897 | 44/18723 | 1.64e-04 | 3.12e-03 | 17 |
| GO:00514021 | Colorectum | SER | neuron apoptotic process | 60/2897 | 246/18723 | 1.65e-04 | 3.13e-03 | 60 |
| GO:00430381 | Colorectum | SER | amino acid activation | 17/2897 | 45/18723 | 2.25e-04 | 3.91e-03 | 17 |
| GO:00064171 | Colorectum | SER | regulation of translation | 100/2897 | 468/18723 | 3.76e-04 | 5.74e-03 | 100 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AARS | SNV | Missense_Mutation | novel | c.2569N>A | p.Leu857Ile | p.L857I | P49588 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| AARS | SNV | Missense_Mutation | c.1823N>T | p.Thr608Met | p.T608M | P49588 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| AARS | SNV | Missense_Mutation | c.1934N>G | p.Ser645Cys | p.S645C | P49588 | protein_coding | deleterious(0.02) | possibly_damaging(0.765) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| AARS | SNV | Missense_Mutation | c.1546N>T | p.Val516Leu | p.V516L | P49588 | protein_coding | tolerated(0.2) | possibly_damaging(0.5) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| AARS | SNV | Missense_Mutation | c.1327N>A | p.Glu443Lys | p.E443K | P49588 | protein_coding | tolerated(0.62) | benign(0.013) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| AARS | SNV | Missense_Mutation | c.1367N>C | p.Gly456Ala | p.G456A | P49588 | protein_coding | tolerated(0.39) | benign(0.007) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AARS | SNV | Missense_Mutation | c.445N>C | p.Asp149His | p.D149H | P49588 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| AARS | SNV | Missense_Mutation | novel | c.1678G>C | p.Glu560Gln | p.E560Q | P49588 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| AARS | SNV | Missense_Mutation | novel | c.634N>G | p.Leu212Val | p.L212V | P49588 | protein_coding | tolerated(0.16) | possibly_damaging(0.85) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| AARS | SNV | Missense_Mutation | novel | c.1459N>C | p.Tyr487His | p.Y487H | P49588 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-LL-A5YN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |